Faheem Hasnain
CIK 1352620 · President & CEO · last filed 2026-08-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.10M
Companies
12
Total Filings
95
Lifetime Open-Market Net
-$20.89M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GOSS | President & CEO | 6,245,866 | $0.16 | $1.02M | $3.22M | 22 | 2026-08-26 |
| KURA | Director | 23,983 | $12.86 | $308.4K | -$291.2K | 13 | 2026-06-04 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 10,791 | $58.70 | $633.4K | $300.0K | 8 | 2024-01-23 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 55,000 | $0.01 | $280 | $0 | 1 | 2021-02-26 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 16,114 | — | — | $1.20M | 5 | 2019-10-04 |
| Receptos, Inc. (RCPT) Delisted | President & CEO | 0 | — | — | -$21.89M | 5 | 2015-08-27 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 3 | 2014-11-12 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 24,519 | — | — | $0 | 7 | 2013-01-03 |
| FACT | President & CEO | 102,667 | $10.70 | $1.10M | $0 | 4 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | President & CEO | 125,000 | — | — | $0 | 1 | 2008-10-03 |
| BIIB | EVP, Oncology/Rheumatology SBU | 25,454 | $222.65 | $5.67M | -$3.43M | 12 | 2008-07-10 |
| TERCICA INC (TRCA) Delisted | Director | — | $7.87 | — | $0 | 1 | 2008-02-28 |
Recent Filings · Page 10 of 10
95 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-05-24 | BIIB | Sell (S) | −7,446 | -$364.9K | EDGAR |
| 2007-03-16 | BIIB | Mixed | +3,999 | -$98.2K | EDGAR |
| 2007-03-16 | BIIB | Mixed | +3,999 | -$98.2K | EDGAR |
| 2007-02-14 | BIIB | Grant (A) | +15,000 | $0 | EDGAR |
| 2007-02-08 | BIIB | Mixed | +3,447 | -$98.9K | EDGAR |
Showing 91–95 of 95
Prev
Page 10 of 10
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.